Skip to main content
Cachet Pharmaceutical Co., Ltd. logo

Cachet Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002462 ISIN · CNE100000SN0 LEI · 300300CBONJS7HUOCX64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2014-10-23 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002462

About Cachet Pharmaceutical Co., Ltd.

https://www.cachet.com.cn

Cachet Pharmaceutical Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive wholesale network and a chain of retail pharmacies, providing comprehensive supply chain solutions to healthcare institutions and end-consumers. Its core operations include the procurement, storage, and logistics of western medicines, traditional Chinese medicines, and high-value medical consumables. Cachet Pharmaceutical emphasizes modern logistics management and professional pharmaceutical services, leveraging a robust distribution infrastructure to ensure the efficient delivery of healthcare products. The company also focuses on hospital supply chain integration and community-based retail services to enhance healthcare accessibility.

Recent filings

Filing Released Lang Actions
第四届董事会第十八次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolution from the 18th meeting of the 4th Board of Directors of 嘉事堂药业股份有限公司. It states that the board approved the 2014 third quarter report and confirms the authenticity and completeness of the report. The document also mentions that the full 2014 third quarter report was published on October 24, 2014, on an external website and in newspapers. The document itself is short (662 characters) and serves as a formal announcement of the board meeting resolution and the approval of the quarterly report, rather than containing the full financial report or detailed financial data. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a formal announcement related to corporate governance and report approval but does not contain the full interim report itself.
2014-10-23 Chinese
2014年第三季度报告正文（已取消）
Interim / Quarterly Report Classification · 95% confidence The document is titled as 嘉事堂药业股份有限公司 2014 年第三季度报告正文, which translates to Jia Shi Tang Pharmaceutical Co., Ltd. 2014 Third Quarter Report. It contains detailed financial data, including main accounting data, financial indicators, shareholder changes, and important matters related to the quarter. The document includes comprehensive financial statements and analysis for the third quarter of 2014, such as revenue, net profit, cash flow, and detailed notes on acquisitions and investments. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content matches the characteristics of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year and contains substantive financial data and analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). 9M 2014
2014-10-23 Chinese
关于最近五年被证券监管部门和交易所采取监管措施或处罚情况的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from 嘉事堂药业股份有限公司 regarding regulatory measures and penalties imposed by securities regulatory authorities and stock exchanges over the past five years. It includes descriptions of regulatory opinions, inquiry letters, regulatory letters, and the company's corresponding rectification measures. The content focuses on compliance, governance issues, insider trading violations, and responses to regulatory inquiries. It does not contain financial statements, earnings data, or typical annual or interim report content. The document is lengthy (9,349 characters) and provides comprehensive regulatory and compliance information rather than financial results or management discussion. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2014-09-26 Chinese
关于向所属的医疗器械控股子公司增资的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about the company's capital increase (增资) to its controlled medical device subsidiaries. It includes extensive information on the capital amounts, shareholder contributions, changes in registered capital, and procedural authorizations for business registration changes. The document does not present financial statements or comprehensive financial performance data but focuses on the capital injection details and shareholder structure. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is not an annual or interim report, audit report, or earnings release, nor is it a regulatory filing or announcement of a report publication. Therefore, the correct classification is CAP.
2014-09-26 Chinese
关于第四届董事会第十七次会议决议的公告
Board/Management Information Classification · 100% confidence The document is an announcement of resolutions passed at the 17th meeting of the 4th Board of Directors of 嘉事堂药业股份有限公司, dated September 26, 2014. It details the election of board committee members and approval of capital increases in subsidiaries. The content focuses on board decisions and management appointments rather than financial results or reports. There is no indication of financial statements or audit information. Therefore, this document fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification, so it is correctly classified as MANG.
2014-09-26 Chinese
2014年第一次临时股东大会会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2014 first extraordinary general meeting of shareholders of 嘉事堂药业股份有限公司. It includes voting results on various proposals such as issuance of convertible bonds, amendments to company articles, election of board members, and other corporate governance matters. The document contains detailed voting outcomes and legal opinions confirming the validity of the meeting and resolutions. It is not a financial report, earnings release, or management discussion, but rather an official record of shareholder meeting decisions and voting results. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail support a high confidence classification.
2014-09-26 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.